Figure 3 | Scientific Reports

Figure 3

From: A CRISPR/Cas13-based approach demonstrates biological relevance of vlinc class of long non-coding RNAs in anticancer drug response

Figure 3

Time course of the survival challenge. (a–c) Cell numbers (Y-axes) for the different times (X-axes) of imatinib (a), mirin (b) or etoposide (c) treatments in the presence or absence of Dox. The blue arrows indicate drug treatments, error bars show the SE of three biological replicas. (d) Coverage of gRNAs observed after each drug treatment, error bars indicate the SE of 12 samples (6 +Dox and 6 −Dox NGS libraries, respectively) or 4 control samples before drug treatment.

Back to article page